Translation of highly promising basic science research into clinical applications

被引:225
|
作者
Contopoulos-Ioannidis, DG
Ntzani, EE
Ioannidis, JPA
机构
[1] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin Trials & Evidence Based Med Unit, GR-45110 Ioannina, Greece
[2] Univ Ioannina, Sch Med, Dept Pediat, GR-45110 Ioannina, Greece
[3] Washington Univ, Sch Med & Hlth Sci, Dept Pediat, Washington, DC USA
[4] Tufts Univ New England Med Ctr, Div Clin Care Res, Boston, MA USA
来源
AMERICAN JOURNAL OF MEDICINE | 2003年 / 114卷 / 06期
关键词
INSTITUTES-OF-HEALTH; ENKEPHALINASE INHIBITOR; CONTROLLED-TRIAL; VIRUS-VACCINE; AVIAN-HUMAN; EFFICACY; INFANTS; RETINOL; CANCER; ACID;
D O I
10.1016/S0002-9343(03)00013-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE: To evaluate the predictors of and time taken for the translation of highly promising basic research, into clinical experimentation and use. METHODS: We identified 101 articles, published between 1979 and 1983 in six major basic science journals, which clearly stated that the technology studied had novel therapeutic or preventive promises. Each case was evaluated for whether the promising finding resulted in relevant randomized controlled trials and clinical use. Main outcomes included the time to published trials, time to published trials with favorable results ("positive" trials), and licensed clinical use. RESULTS: By October 2002, 27 of the promising technologies had resulted in at least one published randomized trial, 19 of which had led to the publication of at least one positive randomized trial. Five basic science findings are currently licensed for clinical use, but only one has been used extensively for the licensed indications. Promising technologies that did not lead to, a published human study within 10 to 12 years were unlikely to be tested in humans subsequently. Some form of industry involvement in the basic science publication was the strongest predictor of clinical experimentation, accelerating the process by about eightfold (95% confidence interval: 3 to 19) when an author had industry affiliations. CONCLUSION: Even the most promising findings of basic research take a long time to translate into clinical experimentation, and adoption in clinical practice is rare. Am J Med. 2003; 114:477-484. (C) 2003 by Excerpta Medica Inc.
引用
收藏
页码:477 / 484
页数:8
相关论文
共 50 条
  • [11] The Basic Science and Clinical Applications of Osteochondral Allografts
    Strauss, Eric J.
    Sershon, Robert
    Barker, Joseph U.
    Kercher, James
    Salata, Michael
    Verma, Nikhil N.
    BULLETIN OF THE HOSPITAL FOR JOINT DISEASES, 2012, 70 (04): : 217 - 223
  • [12] Ototoxicity - Basic science and clinical applications - Introduction
    Iurato, S
    Henderson, D
    Quaranta, A
    Salvi, RJ
    OTOTOXICITY: BASIC SCIENCE AND CLINICAL APPLICATIONS, 1999, 884 : IX - XI
  • [13] Tendon pathology: Basic science and clinical applications
    Kannus, P
    SPORTS EXERCISE AND INJURY, 1997, 3 (02): : 62 - 75
  • [14] Glutamine: From basic science to clinical applications
    Ziegler, TR
    Szeszycki, EE
    Estivariz, CF
    Puckett, AB
    Leader, LM
    NUTRITION, 1996, 12 (11-12) : S68 - S70
  • [15] Colorectal cancer: basic science & clinical applications
    Arends, MJ
    Shepherd, NA
    JOURNAL OF PATHOLOGY, 2006, 208 : 33A - 33A
  • [16] Lost in Translation-Basic Science in the Era of Translational Research
    Fang, Ferric C.
    Casadevall, Arturo
    INFECTION AND IMMUNITY, 2010, 78 (02) : 563 - 566
  • [17] Agent based models of acute inflammation: Translating basic science research into clinical applications
    An, G
    SHOCK, 2004, 21 : 98 - 98
  • [18] Basic research is the foundation and driving force for clinical translation
    Li, Gang
    JOURNAL OF ORTHOPAEDIC TRANSLATION, 2024, 45 : A1 - A2
  • [19] Editorial: Juvenile Spondyloarthritis: From Basic Science to Clinical Translation
    Harjacek, Miroslav
    Joos, Rik
    Vargas, Ruben Burgos
    FRONTIERS IN MEDICINE, 2022, 9
  • [20] Remyelination in multiple sclerosis: from basic science to clinical translation
    Lubetzki, Catherine
    Zalc, Bernard
    Williams, Anna
    Stadelmann, Christine
    Stankoff, Bruno
    LANCET NEUROLOGY, 2020, 19 (08): : 678 - 688